MedPath

Stoke Therapeutics

Stoke Therapeutics logo
🇺🇸United States
Ownership
Public
Established
2014-01-01
Employees
110
Market Cap
$730.2M
Website
http://www.stoketherapeutics.com
Introduction

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Clinical Trials

6

Active:1
Completed:2

Trial Phases

3 Phases

Phase 1:3
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (60.0%)
Phase 2
1 (20.0%)
Phase 3
1 (20.0%)

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Phase 3
Recruiting
Conditions
Dravet Syndrome
Interventions
Other: Sham Comparator
First Posted Date
2025-03-12
Last Posted Date
2025-07-17
Lead Sponsor
Stoke Therapeutics, Inc
Target Recruit Count
150
Registration Number
NCT06872125
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

and more 37 locations

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Phase 2
Conditions
Dravet Syndrome
Interventions
First Posted Date
2021-02-05
Last Posted Date
2025-05-21
Lead Sponsor
Stoke Therapeutics, Inc
Target Recruit Count
60
Registration Number
NCT04740476
Locations
🇺🇸

University of California San Francisco Medical Center, San Francisco, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

and more 14 locations

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

Phase 1
Completed
Conditions
Dravet Syndrome
Interventions
First Posted Date
2020-06-22
Last Posted Date
2025-05-18
Lead Sponsor
Stoke Therapeutics, Inc
Target Recruit Count
62
Registration Number
NCT04442295
Locations
🇺🇸

UCSF Benioff Children's Hospital, San Francisco, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

and more 15 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.